Understanding how bone marrow-derived cells (BMDCs) enter the central nervous system (CNS) is critical for the development of therapies for brain-related disorders using hematopoietic stem cells. We investigated the brain damages and blood-brain barrier (BBB) modification following either whole-body irradiation or a myeloablative chemotherapy regimen in mice, and the capacity for these treatments to induce the entry of BMDCs into the CNS. Neither treatment had a lasting effect on brain integrity and both were equally efficient at achieving myeloablation. Injection of bone marrow cells from green fluorescent protein (GFP) transgenic mice was able to completely repopulate the hematopoietic niche in the circulation and in hematopoietic organs (thymus and spleen). However, GFP(+) cells only entered the brain following whole-body irradiation. We conclude that myeloablation, damages to the brain integrity, or the BBB and peripheral chimerism are not responsible for the entry of BMDCs into the CNS following irradiation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3727/096368911X593154 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dietary blueberry before and/or after exposure to HZE particle radiation attenuates neuroinflammation, oxidative stress, glial cell activation, and memory deficits in rats.
J Nutr
January 2025
USDA-ARS, Jean Mayer Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA. Electronic address:
Background: Acute neuroinflammatory and oxidative-stress (OS)-inducing stressors, such as high energy and charge (HZE) particle irradiation, produce accelerated aging in the brain. Anti-inflammatory and antioxidant foods, such as blueberries (BB), attenuate neuronal and cognitive deficits when administered to rodents before or both before and after HZE particle exposure. However, the effects of post-stressor treatments are unknown and may be important to repair initial damage and prevent progressive neurodegeneration.
View Article and Find Full Text PDFCharacterization and dosimetric predictors for absolute lymphocyte count changes during neoadjuvant chemoradiotherapy with or without pembrolizumab for esophageal squamous cell carcinoma: an analysis of a prospective cohort.
Radiat Oncol
January 2025
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, P.R. China.
Aim: To characterize the differences of dynamic changes for absolute lymphocyte count (ALC) among esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiotherapy (nCRT) with or without pembrolizumab, as well as to investigate the clinical and lymphocyte-related organs dosimetric parameters that would impact ALC nadir during nCRT.
Materials And Methods: A total of 216 ESCC patients who received nCRT (with pembrolizumab 144; without pembrolizumab: 72) were identified from a prospective cohort. Weekly and 1-month post-nCRT ALC were identified.
CXCR4-directed endoradiotherapy with [Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed/refractory acute myeloid leukemia.
Theranostics
January 2025
Department of Internal Medicine III, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Article Synopsis
- Despite improvements in targeted therapy for Acute Myeloid Leukemia (AML), the prognosis remains poor, particularly for patients with relapsed or refractory disease.
- Allogeneic hematopoietic stem cell transplantation (alloSCT) is the main curative option for high-risk patients, but the best conditioning approach is still uncertain for those who are chemotherapy-refractory.
- A study on seven AML patients who received CXCR4-directed endoradiotherapy (ERT) combined with total body irradiation and chemotherapy prior to alloSCT showed promising outcomes, with 6 out of 7 patients achieving response and successful engraftment, offering insights into a potentially effective treatment strategy for advanced cases.
Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease.
Ann Med
December 2025
Department of Hematology, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Hangzhou, China.
Background: The management of high-risk acute myeloid leukaemia (AML) remains challenging, highlighting the need for innovative conditioning strategies beyond current regimens.
Methods: In the present single-arm study, a FACT regimen comprised of low-dose total body irradiation (TBI) with fludarabine, cytarabine and cyclophosphamide was employed to treat cytogenetically high-risk AML patients exhibiting pre-transplant active disease. This clinical trial is registered in the Chinese Clinical Trial Registry with the registration number ChiCTR2000035111.
Training and temporally validating an NTCP model of acute toxicity after whole breast radiotherapy, including the impact of advanced delivery techniques.
Radiother Oncol
December 2024
IRCCS San Raffaele Scientific Institute, Medical Physics Dept., Milan, Italy. Electronic address:
Purpose: The aim is to train and validate a multivariable Normal Tissue Complication Probability (NTCP) model predicting acute skin reactions in patients with breast cancer receiving adjuvant Radiotherapy (RT).
Methods And Materials: We retrospectively reviewed 1570 single-institute patients with breast cancer treated with whole breast irradiation (40 Gy/15fr). The patients were divided into training (n = 878, treated with 3d-CRT, from 2009 to 2017) and validation cohorts (n = 692, treated from 2017 to 2021, including advanced RT techniques).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!